Literature DB >> 19513521

Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.

Sibyll Hein1, Sven Mahner, Christine Kanowski, Thomas Löning, Fritz Jänicke, Karin Milde-Langosch.   

Abstract

Jun and Fos proteins form the transcription factor activating protein 1 (AP-1). They play a role in cell proliferation, malignant transformation and invasion in various tumors. The aim of the current study was to characterize the role of AP-1 in ovarian cancer. Fifty-six ovarian tumors of different invasive potential including 13 metastases as well as 5 ovarian cancer cell lines were analyzed by Western blot analysis regarding their expression of pc-Jun, Jun B, Jun D, c-Fos, Fos B, Fra-1 and Fra-2. In addition, invasion, cell proliferation and migration assays were performed. The expression of pc-Jun, Jun B, Jun D and Fra-2 was higher in invasive cancer compared to benign tumors. In metastases, c-Fos and Fos B expression was significantly lower than in the respective primary ovarian carcinomas. The invasive and proliferative potential of the cells was not associated with AP-1 protein expression. These results suggest that AP-1 proteins are differentially expressed in benign ovarian tumors, tumors with low malignant potential and epithelial ovarian carcinomas and metastases. No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513521     DOI: 10.3892/or_00000422

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  19 in total

Review 1.  Expression and function of FRA1 protein in tumors.

Authors:  Xiaoyan Jiang; Hui Xie; Yingyu Dou; Jing Yuan; Da Zeng; Songshu Xiao
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

2.  The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells.

Authors:  Ji Hee Ha; Jeremy D Ward; Lakshmi Varadarajalu; Sang Geon Kim; Danny N Dhanasekaran
Journal:  Cell Signal       Date:  2013-09-19       Impact factor: 4.315

3.  The prognostic significance of Jun transcription factors in ovarian cancer.

Authors:  Kerstin Eckhoff; Roland Flurschütz; Fabian Trillsch; Sven Mahner; Fritz Jänicke; Karin Milde-Langosch
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-13       Impact factor: 4.553

4.  Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies.

Authors:  Rotem Ben-Hamo; Sol Efroni
Journal:  BMC Syst Biol       Date:  2012-01-11

Review 5.  Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  Biomark Cancer       Date:  2015-09-06

6.  Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.

Authors:  Nana Jin; Hao Wu; Zhengqiang Miao; Yan Huang; Yongfei Hu; Xiaoman Bi; Deng Wu; Kun Qian; Liqiang Wang; Changliang Wang; Hongwei Wang; Kongning Li; Xia Li; Dong Wang
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

7.  Cervical cancer stem cells manifest radioresistance: Association with upregulated AP-1 activity.

Authors:  Abhishek Tyagi; Kanchan Vishnoi; Harsimrut Kaur; Yogesh Srivastava; Bal Gangadhar Roy; Bhudev C Das; Alok C Bharti
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

8.  A computational framework for complex disease stratification from multiple large-scale datasets.

Authors:  Bertrand De Meulder; Diane Lefaudeux; Aruna T Bansal; Alexander Mazein; Amphun Chaiboonchoe; Hassan Ahmed; Irina Balaur; Mansoor Saqi; Johann Pellet; Stéphane Ballereau; Nathanaël Lemonnier; Kai Sun; Ioannis Pandis; Xian Yang; Manohara Batuwitage; Kosmas Kretsos; Jonathan van Eyll; Alun Bedding; Timothy Davison; Paul Dodson; Christopher Larminie; Anthony Postle; Julie Corfield; Ratko Djukanovic; Kian Fan Chung; Ian M Adcock; Yi-Ke Guo; Peter J Sterk; Alexander Manta; Anthony Rowe; Frédéric Baribaud; Charles Auffray
Journal:  BMC Syst Biol       Date:  2018-05-29

9.  c-FOS suppresses ovarian cancer progression by changing adhesion.

Authors:  L Oliveira-Ferrer; K Rößler; V Haustein; C Schröder; D Wicklein; D Maltseva; N Khaustova; T Samatov; A Tonevitsky; S Mahner; F Jänicke; U Schumacher; K Milde-Langosch
Journal:  Br J Cancer       Date:  2013-12-05       Impact factor: 7.640

10.  Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer.

Authors:  Shilpi Gupta; Prabhat Kumar; Harsimrut Kaur; Nishi Sharma; Daman Saluja; Alok C Bharti; Bhudev C Das
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.